Search | Clinical Trials Finder

Conditions: Type 1 Diabetes Mellitus
Interventions: Open-Loop, Closed-Loop; Device
Lead sponsor: University of Virginia; Other
Eligibility: 12 Years to 18 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hypogonadism
Interventions: GnRH antagonist (Acyline); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5; Device
Lead sponsor: Marc Breton; Other
Eligibility: 24 Months to 71 Months
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Stanford, California • Aurora, Colorado • Charlottesville, Virginia

Conditions: Type1 Diabetes
Interventions: Glargine; Biological
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: I-PORT, standard injections; Device · Other
Lead sponsor: Texas Diabetes & Endocrinology, P.A.; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: Recombinant human hyaluronidase PH20 (rHuPH20), Insulin lispro, Insulin glulisine, Insulin aspart; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes Mellitus
Interventions: MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]), CSII (Animas Corporation insulin pump, model IR 1200); Drug · Device
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 8 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Type 1 Diabetes Mellitus
Interventions: Technosphere Insulin Inhalation Powder, Rapid Acting Analog; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes Mellitus
Interventions: Glargine, glargine via insulin pen; Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 60 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions: Arginine hydrochloride, Sodium Chloride 0.9%; Drug
Lead sponsor: David K Carroll; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Fatty Liver Disease, Nonalcoholic
Interventions: metreleptin; Drug
Lead sponsor: Elif Oral; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Thyroid Eye Disease, Graves' Orbitopathy
Interventions: Teprotumumab, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more

Conditions: Type 1 Diabetes Mellitus
Interventions: CloudConnect Report, Will not receive a CloudConnect Report; Other
Lead sponsor: University of Virginia; Other
Eligibility: 12 Years to 17 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diabetes Mellitus
Interventions: Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM); Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Cystic Fibrosis
Interventions: novolog insulin, levemir insulin, placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 10 Years to 25 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Conditions: IGF1 Deficiency
Interventions: Increlex®; Drug
Lead sponsor: Esteve Pharmaceuticals, S.A.; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 7
States / cities: Orange, California • Miami, Florida • Cincinnati, Ohio + 2 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Insulin Glargine 100U/mL, Insulin Degludec, Insulin Glargine 300U/mL; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 1,085 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 142
States / cities: Birmingham, Alabama • Guntersville, Alabama • Gilbert, Arizona + 122 more

Conditions: Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
Interventions: Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 24
States / cities: Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more

Conditions: Type 2 Diabetes
Interventions: Placebo for Nasulin, Nasulin; Other · Drug
Lead sponsor: CPEX Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Chandler, Arizona • Escondido, California • La Jolla, California + 17 more

Conditions: Type 1 Diabetes
Interventions: Xeris glucagon, Lilly glucagon; Drug
Lead sponsor: Steven J. Russell, MD, PhD; Other
Eligibility: 21 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Thyroid Eye Disease (TED)
Interventions: VRDN-003, Placebo; Drug
Lead sponsor: Viridian Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 32
States / cities: Tuscon, Arizona • Inglewood, California • Newport Beach, California + 25 more

Conditions: Healthy Volunteers
Interventions: rHuPH20, Insulin Human Injection, Insulin Lispro Injection; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obesity, Insulin Resistance
Interventions: Anastrazole, Testosterone, Dutasteride, GnRH antagonist; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 24 Years to 51 Years · Male only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: San Diego, California

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin Glargine, Insulin Aspart, Insulin Lispro; Drug
Lead sponsor: University of Miami; Other
Eligibility: 65 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: South Miami, Florida

Search by objective public record fields.

Hypoglycemia Prevention After Exercise in Adolescent T1DM Patients Using a Control to Range System

Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men

The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes

Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM

Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone

Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy

Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes

Satisfaction of Treatment Among Elderly Patients With Insulin Therapy

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management

Oral Anti Diabetic Agents in the Hospital

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus

Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20

Metabolic Effects of Steroids in Obese Men

Simplified Insulin Regimen for the Elderly